UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association

Circulation (New York, N.Y.), 2016-08, Vol.134 (6), p.e32-e69

2016

Volltextzugriff (PDF)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Cancer chemotherapy and pharmacology, 2021-11, Vol.88 (5), p.825-836

2021

Volltextzugriff (PDF)

Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2024-04

2024

Volltextzugriff (PDF)

The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan

Expert review of anticancer therapy, 2023-10, Vol.23 (10), p.1061-1069

2023

Volltextzugriff (PDF)

Implementation of a pharmacist-managed clinic for patients with chronic nonmalignant pain

American journal of health-system pharmacy, 2017-08, Vol.74 (16), p.1229-1235

2017

Volltextzugriff (PDF)

Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients

European journal of clinical pharmacology, 2019-01, Vol.75 (1), p.51-57

2019

Volltextzugriff (PDF)

A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors

Cancers, 2024-04, Vol.16 (8), p.1456

2024

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Clinical cancer research, 2008-07, Vol.14 (14), p.4517-4525

2008

Volltextzugriff (PDF)

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

Cancer chemotherapy and pharmacology, 2018-04, Vol.81 (4), p.659-670

2018

Volltextzugriff (PDF)

Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor‐Resistant Basal Cell Carcinoma Cells via Targeting EGFR‐MAPK‐Akt and Hedgehog Signaling

Photochemistry and photobiology, 2017-07, Vol.93 (4), p.999-1007

2017

Volltextzugriff (PDF)

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

Clinical cancer research, 2020-09, Vol.26 (17), p.4633-4642

2020

Volltextzugriff (PDF)

The intersection between cannabis and cancer in the United States

Critical reviews in oncology/hematology, 2012-07, Vol.83 (1), p.1-10

2012

Volltextzugriff (PDF)

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma

The Annals of pharmacotherapy, 2014-01, Vol.48 (1), p.99

2014

Volltextzugriff (PDF)

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer

The Annals of pharmacotherapy, 2013-02, Vol.47 (2), p.189

2013

Volltextzugriff (PDF)

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-09, Vol.12 (18), p.5471-5480

2006

Volltextzugriff (PDF)

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

Cancer chemotherapy and pharmacology, 2012-03, Vol.69 (3), p.605-612

2012

Volltextzugriff (PDF)

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-08, Vol.18 (15), p.4173-4182

2012

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

Clinical cancer research, 2007-04, Vol.13 (7), p.2091-2099

2007

Volltextzugriff (PDF)

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy

Pharmacotherapy, 2016-01, Vol.36 (1), p.99-116

2016

Volltextzugriff (PDF)

Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors

Journal of oncology pharmacy practice, 2015-08, Vol.21 (4), p.258-267

2015

Volltextzugriff (PDF)

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

British journal of clinical pharmacology, 2019-11, Vol.85 (11), p.2499-2511

2019

Volltextzugriff (PDF)

Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center

Journal of oncology pharmacy practice, 2020-09, Vol.26 (6), p.1369-1373

2020

Volltextzugriff (PDF)

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

Anti-cancer drugs, 2008-01, Vol.19 (1), p.77-84

2008

Volltextzugriff (PDF)

A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors

Molecular cancer therapeutics, 2008-12, Vol.7 (12), p.3685-3694

2008

Volltextzugriff (PDF)

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Molecular cancer therapeutics, 2018-01, Vol.17 (1), p.215-221

2018

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(63)
Berichte
(1)

Sprache

Englisch
(64)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Humans
(38)
Female
(26)
Male
(26)
Middle Aged
(26)
Oncology
(24)
Pharmacology & Pharmacy
(24)
Aged
(23)
Neoplasms - Drug Therapy
(22)
Adult
(21)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Pharmacology. Drug Treatments
(13)
Tumors
(13)
Antineoplastic Agents - Adverse Effects
(12)
Dose-Response Relationship, Drug
(11)
Antineoplastic Agents - Therapeutic Use
(10)
Antineoplastic Agents
(9)
Antineoplastic Agents - Pharmacokinetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors

The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan

Implementation of a pharmacist-managed clinic for patients with chronic nonmalignant pain

Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients

A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor‐Resistant Basal Cell Carcinoma Cells via Targeting EGFR‐MAPK‐Akt and Hedgehog Signaling

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

The intersection between cannabis and cancer in the United States

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy

Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Suchergebnisse filtern